Premium
Commentary: ILAE Definition of Epilepsy
Author(s) -
BenMenachem Elinor
Publication year - 2014
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/epi.12577
Subject(s) - epilepsy , clinical neurology , task (project management) , medicine , task force , psychology , psychiatry , family medicine , neuroscience , political science , management , public administration , economics
Trying to define epilepsy and give an operational definition to the term is a daunting task. The definition must be user friendly and be applicable in clinics around the world. The authors and members of the Task Force of the International League Against Epilepsy (ILAE) have been diligent and have labored for 9 years to produce this document, which in format is a consensus statement. The need for a new definition of epilepsy was sparked by the controversy that patients with one unprovoked seizure may have epilepsy. To stick religiously to the old definition of two unprovoked seizures no longer seemed realistic. After several drafts of The Practical Clinical Definition of Epilepsy document, it was presented to the members of the ILAE for comments at the Presidential Symposium at the ILAE Congress in Montreal on June 24, 2013. Most epileptologists (about 1,000 in the audience) at that meeting were in agreement with the cases presented, and consensus was high on whether epilepsy had occurred. In other words, the document has been through several tests, and now it is poised to be accepted by the international epilepsy community. The cases provided in the document and presented at the symposium are instructive and aid the reader in understanding the concepts presented in the manuscript. They will be useful teaching aids in the future. However, some small problems remain that will need to be addressed. I believe the biggest challenge for the clinician out in the field will be to estimate risk and decide whether the patient should be treated. Concrete advice will be needed to determine the approximate risk of new seizures for each patient. Even if the authors state that there is no burden on the treating physician to specify recurrence risk in a particular circumstance, physicians as well as patients will feel a certain anxiety about the ambiguity. One of the more helpful aids in determining risk is from the Medical Research Council Multicenter Trial for Early Epilepsy and Single seizures (MESS) study. This study is cited in the Practical Clinical Definition of Epilepsy document, but the point system used in the MESS study to estimate risk is not clarified. I would therefore like to take this opportunity to present the point system developed from the MESS study. It can be helpful in determining if a patient should be treated immediately or can if treatment can be deferred until the occurrence of a second unprovoked seizure. In this (the MESS) study, a four-point system was derived (with a maximum of three points possible for patients presenting with only a single seizure). If a patient has only one unprovoked seizure but no underlying neurologic disorder and normal electroencephalography (EEG), he is given a score of 0; this patient is categorized as a low risk patient. In the MESS study the risk of having another unprovoked seizure within a 1 year period was 0.26 for the treated group and 0.19 for the deferred group. The risk for the 5 year period was 0.39 for the treated group and 0.30 for the deferred group. In other words if treatment is deferred there would be no effect on the recurrence rate and the risk rate would be low (<70%). If, on the other hand, a patient has either an abnormal EEG finding of any type or an underlying neurologic disorder, then one point is given; one point implies a medium risk. The probability then of a second seizure for the medium risk group is 0.24 at 1 year for the treated group and 0.35 for the deferred group. By 5 years the risk is 0.39 and 0.56, respectively. In order words, the risk is still <70%, but patients who had their treatment deferred in the MESS study had a worse outcome. If, however, there is an abnormal EEG finding and an underlying neurologic deficit, the risk increases to two points and is classified as high risk. By 1 year, the recurrence rate in the study was 0.36 for the treated group and 0.59 for the deferred group. By 5 years the results were even more impressive. The patients who received treatment after the first seizure had a recurrence rate of 0.50, whereas those patients for whom treatment was deferred by only one seizure had a recurrence rate of 0.73. The preceding system presented by Kim et al. is applicable in the clinic. The system can help to decide when a sinWiley Periodicals, Inc. © 2014 International League Against Epilepsy